Ben-Yedidia T.

Ben-Yedidia T, Arnon R.
Expert Rev Vaccines. 2007 Dec;6(6):939-48. Review.

Flagella as a platform for epitope-based vaccines
Ben-Yedidia T, Arnon R.
Isr Med Assoc J. 2006 May;8(5):316-8.

Towards an epitope-based human vaccine for influenza
Ben-Yedidia T, Arnon R.
Hum Vaccin. 2005 May-Jun;1(3):95-101. Epub 2005 May 15.

Old and new vaccine approaches
Arnon R, Ben-Yedidia T.
Int Immunopharmacol. 2003 Aug; 3(8):1195-204.

Peptide-based synthetic recombinant vaccines with anti-viral efficacy
Arnon R, Tarrab-Hazdai R, Ben-Yedidia T.
Biologicals. 2001 Sep-Dec;29(3-4):237-42.

Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni
Ben-Yedidia T, Tarrab-Hazdai R, Schechtman D, Arnon R.
Infect Immun. 1999 Sep;67(9):4360-6.

Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection
Ben-Yedidia T, Marcus H, Reisner Y, Arnon R.
Int Immunol. 1999 Jul;11(7):1043-51.

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine
Ben-Yedidia T, Arnon R.
Immunol Lett. 1998 Nov;64(1):9-15.

Efficacy of anti-influenza peptide vaccine in aged mice
Ben-Yedidia T, Abel L, Arnon R, Globerson A.
Mech Ageing Dev. 1998 Aug 1;104(1):11-23.

Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection
Arnon R, Levi R.
Adv Exp Med Biol. 1996;397:23-9.

Design of peptide and polypeptide vaccines
Ben-Yedidia T, Arnon R.
Curr Opin Biotechnol. 1997 Aug;8(4):442-8.